Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research

Gunver S Kienle, Anja Glockmann, Michael Schink, Helmut Kiene, Gunver S Kienle, Anja Glockmann, Michael Schink, Helmut Kiene

Abstract

Background: Viscum album L. extracts (VAE, European mistletoe) are a widely used medicinal plant extract in gynaecological and breast-cancer treatment.

Methods: Systematic review to evaluate clinical studies and preclinical research on the therapeutic effectiveness and biological effects of VAE on gynaecological and breast cancer. Search of databases, reference lists and expert consultations. Criteria-based assessment of methodological study quality.

Results: 19 randomized (RCT), 16 non-randomized (non-RCT) controlled studies, and 11 single-arm cohort studies were identified that investigated VAE treatment of breast or gynaecological cancer. They included 2420, 6399 and 1130 patients respectively. 8 RCTs and 8 non-RCTs were embedded in the same large epidemiological cohort study. 9 RCTs and 13 non-RCTs assessed survival; 12 reported a statistically significant benefit, the others either a trend or no difference. 3 RCTs and 6 non-RCTs assessed tumour behaviour (remission or time to relapse); 3 reported statistically significant benefit, the others either a trend, no difference or mixed results. Quality of life (QoL) and tolerability of chemotherapy, radiotherapy or surgery was assessed in 15 RCTs and 9 non-RCTs. 21 reported a statistically significant positive result, the others either a trend, no difference, or mixed results. Methodological quality of the studies differed substantially; some had major limitations, especially RCTs on survival and tumour behaviour had very small sample sizes. Some recent studies, however, especially on QoL were reasonably well conducted. Single-arm cohort studies investigated tumour behaviour, QoL, pharmacokinetics and safety of VAE. Tumour remission was observed after high dosage and local application. VAE application was well tolerated. 34 animal experiments investigated VAE and isolated or recombinant compounds in various breast and gynaecological cancer models in mice and rats. VAE showed increase of survival and tumour remission especially in mice, while application in rats as well as application of VAE compounds had mixed results. In vitro VAE and its compounds have strong cytotoxic effects on cancer cells.

Conclusion: VAE shows some positive effects in breast and gynaecological cancer. More research into clinical efficacy is warranted.

References

    1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592. doi: 10.1093/annonc/mdl498.
    1. Stat Bite: Number of Cancer Survivors by Site, 2003. J Natl Cancer Inst. 2006;98(21):1514.
    1. Fasching PA, Thiel F, Nicolaisen-Murmann K, Rauh C, Engel J, Lux MP, Beckmann MW, Bani MR. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer. 2007;55:1277–1284. doi: 10.1007/s00520-007-0231-1.
    1. Helyer LK, Chin S, Chuim BK, Fitzgerald B, Verma S, Rakovitch E, Dranitsaris G, Clemons M. The use of complementary and alternative medicines among patients with locally advanced breast cancer – a descriptive study. BMC Cancer. 2006;6:39. doi: 10.1186/1471-2407-6-39.
    1. DiGianni LM, Garber JE, WIner EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol. 2002;20:34s–38s.
    1. Boon HS, Olatunde F, Zick SM. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Woman's Health. 2007;7:4. doi: 10.1186/1472-6874-7-4.
    1. Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernandez-Ortega P, Panteli V, Margulies A, Gudmundsdottir G, Milovics L, Ozden G, Platin N, Patiraki E. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 2006;14:260–267. doi: 10.1007/s00520-005-0883-7.
    1. Molassiotis A, Browall M, Milovics L, Panteli V, Patiraki E, Fernandez-Ortega P. Complementary and alternative medicine use in patients with gynecological cancers in Europe. International Journal of Gynecological Cancer. 2006;16:219–224. doi: 10.1111/j.1525-1438.2006.00309.x.
    1. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. In: Elisabetsky E, Etkin NL, editor. Ethnopharmacology Encyclopedia of Life Support Systems (EOLSS), developed under the Auspices of the UNESCO. Oxford, UK, Eolss Publishers; 2006.
    1. Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16:655–663. doi: 10.1093/annonc/mdi110.
    1. Endo Y, Tsurugi K, Franz H. The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. FEBS Letters. 1988;231:378–380. doi: 10.1016/0014-5793(88)80853-6.
    1. Stirpe F, Sandvig K, Olsnes S, Pihl A. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. The Journal of Biological Chemistry. 1982;257:13271–13277.
    1. Stirpe F, Barbieri L, Battelli MG, Soria M, Lappi DA. Ribosome-inactivating proteins from plants: present status and future prospects. Biotechnology (N Y) . 1992;10(4):405–412. doi: 10.1038/nbt0492-405.
    1. Peumans WJ, Verhaert P, Pfüller U, Van Damme EJM. Isolation and partial characterization of a small chitin-binding lectin from mistletoe (Viscum album) FEBS Letters. 1996;396:261–265. doi: 10.1016/0014-5793(96)01108-8.
    1. Klett CY, Anderer FA. Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from Viscum album extract. Arzneimittelforschung . 1989;39(12):1580–1585.
    1. Mueller EA, Anderer FA. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother. 1990;32:221–227. doi: 10.1007/BF01741704.
    1. Orhan DD, Küpeli E, Yesilada E, Ergun F. Anti-inflammatory and antinociceptive activity of flavonoids isolated from VISCUM ALBUM ssp. ALBUM. Z Naturforsch C. 2006;61(1-2):26–30.
    1. Winkler K, Leneweit G, Schubert R. Characterization of membrane vesicles in plant extracts. Colloids and surfaces B, Biointerfaces. 2005;45:57–65. doi: 10.1016/j.colsurfb.2005.07.006.
    1. Jager S, Winkler K, Pfuller U, Scheffler A. Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. Planta Med. 2007;73:157–162. doi: 10.1055/s-2007-967106.
    1. Kienle GS, Kiene H. Die Mistel in der Onkologie – Fakten und konzeptionelle Grundlagen. Stuttgart, New York: Schattauer Verlag; 2003.
    1. Büssing A, (ed) Mistletoe The Genus Viscum. Amsterdam: Hardwood Academic Publishers; 2000.
    1. Eggenschwiler J, von BL, Stritt B, Pruntsch D, Ramos M, Urech K, Rist L, Simoes-Wust AP, Viviani A. Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata) BMC Complement Altern Med. 2007;7:14. doi: 10.1186/1472-6882-7-14.
    1. Büssing A, Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999;19:23–28.
    1. Elsässer-Beile U, Lusebrink S, Grussenmeyer U, Wetterauer U, Schultze-Seemann W. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. Arzneimittelforschung . 1998;48(12):1185–1189.
    1. Valentiner U, Pfüller U, Baum C, Schumacher U. The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology. 2002;171:187–199. doi: 10.1016/S0300-483X(01)00581-9.
    1. Siegle I, Fritz P, McClellan M, Gutzeit S, Murdter TE. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res. 2001;21:2687–2691.
    1. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Research. 1999;59:2083–2090.
    1. Mueller EA, Anderer FA. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: Chemical specificity of target cell recognition. Cancer Research. 1990;50:3646–3651.
    1. Zhu HG, Zollner TM, Klein-Franke A, Anderer FA. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+CD3- natural killer (NK) cells and CD+T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets. J Cancer Res Clin Oncol. 1994:383–388. doi: 10.1007/BF01240135.
    1. Park W-B, Lyu SY, Kim JH, Choi SH, Chung HK, Ahn SH, Hong SY, Yoon TJ, Choi MJ. Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biother Radiopharm. 2001;16:439–447. doi: 10.1089/108497801753354348.
    1. Van Huyen JP, Bayry J, Delignat S, Gaston AT, Michel O, Bruneval P, Kazatchkine MD, Nicoletti A, Kaveri SV. Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. Mol Med. 2002;8:600–606.
    1. Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C, European Organization for Research and Treatment of Cancer New Drug Development Group Phase I trial on intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol. 2004;15:1816–1824. doi: 10.1093/annonc/mdh469.
    1. Schöffski P, Breidenbach I, Krauter J, Bolte O, Stadler M, Ganser A, Wilhelm-Ogunbiyi K, Lentzen H. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer. 2005;41:1431–1438. doi: 10.1016/j.ejca.2005.03.019.
    1. Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kiene H. Mistletoe in cancer – a systematic review on controlled clinical trials. Eur J Med Res. 2003;8:109–119.
    1. Stauder H, Kreuser E-D. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie. 2002;25:374–380. doi: 10.1159/000066058.
    1. Kienle GS, Kiene H. Complementary Cancer Therapy: A Systematic Review of Prospective Clinical Trials on Anthroposophic Mistletoe Extracts. Eur J Med Res. 2007;12:103–119.
    1. Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomized clincial trials. Int J Cancer. 2003;107:262–267. doi: 10.1002/ijc.11386.
    1. Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008:CD003297.
    1. Lange-Lindberg AM, Velasco Garrido M, Busse R. Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie maligner Erkrankungen. . GMS Health Technol Assess 2006; 2:Doc18 (20060919) 2006.
    1. Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking Systematic Reviews of Research on Effectiveness CRD'S Guidance for those Carrying Out or Commissioning Reviews CRD Report Number 4. 2. University of York: NHS Centre for Reviews and Dissemination; 2001.
    1. Kleijnen J, Knipschild P. Mistletoe treatment for cancer – review of controlled trials in humans. Phytomedicine. 1994;1:255–260.
    1. Jach R, Basta A. Iscador QuS and human recombinant interferon alpha (Intron A) in cervical intraepithelial neoplasia (CIN) Przeglad Lekarski. 1999;56:86–88.
    1. Jach R, Basta A, Szczudrawa A. Role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 with concurrent HPV infection. Ginekol Pol. 2003;74:729–735.
    1. Mansky PJ, Wallerstedt DB, Monahan BP, Lee C, Sannes T, Stagl J, Blackman MA, Swain SL, Grem J. Phase I study of mistletoe extract/gemcitabine combination treatment in patients with advanced solid tumors. Onkologie. 2008;31:200. doi: 10.1159/000119121.
    1. Schink M, Tröger W, Goyert A, Scheuerecker H, Selbmann K, Glaser F. Zusammenhang der NK-Zellaktivität gegen autologe Tumor- und K562-Zellen mit dem klinischen Verlauf unter Misteltherapie. Forsch Komplementärmed. 2006;13:147–155. doi: 10.1159/000092624.
    1. Bar-Sela G, Goldberg H, Beck D, Amit A, Kuten A. Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. Anticancer Res. 2006;26:709–714.
    1. Tröger W, Matijaševic M, Ždrale Z, Tisma N, Jezdic S. Additional therapy with mistletoe extracts in breast cancer patients receiving chemotherapy: a prospective randomized open label pilot study. In: Scheer R, Alban S, Becker H, Holzgrabe U, Kemper FH, Kreis W, Matthes H, Schilcher H, editor. Die Mistel in der Tumortherapie 2 – Aktueller Stand der Forschung und klinische Anwendung. Essen, KVC-Verlag; 2009. pp. 509–521.
    1. Büssing A, Brückner U, Enser-Weis U, Schnelle M, Schumann A, Schietzel M, Hatzmann W, Hackmann J. Modulation of chemotherapy-associated immunosuppression by intravenous application of Viscum album L. extract (Iscador): a randomised physe II study. European Journal for Integrative Medicine. 2008;1:S44–S54.
    1. Grossarth-Maticek R, Ziegler R. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador) Eur J Med Res. 2008;13:107–120.
    1. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung. 2007;57(10):665–678.
    1. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador®) Forsch Komplementärmed. 2007;14:140–147. doi: 10.1159/000102956.
    1. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) – Supplementary materials. 2006 doi: 10.1159/000095378.
    1. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) Forsch Komplementärmed. 2006;13:285–292. doi: 10.1159/000095378.
    1. Semiglasov VF, Stepula VV, Dudov A, Schnitker J, Mengs U. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2006;26:1519–1530.
    1. Auerbach L, Dostal V, Václavik-Fleck I, Kubista E, Rosenberger A, Rieger S, Tröger W, Schierholz JM. Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiven randomisierten doppelblinden Studie. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editor. Fortschritte in der Misteltherapie Aktueller Stand der Forschung und klinischen Anwendung. Essen, KVC Verlag; 2005. pp. 543–554.
    1. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res. 2004;24:303–309.
    1. Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2004;24:1293–1302.
    1. Borrelli E. Evaluation of the quality of life in breast cancer patients undergoing lectin standardized mistletoe therapy. Minerva Medica. 2001;92:105–107.
    1. Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001;7:57–78.
    1. Kim M-H, Park Y-K, Lee S-H, Kim S-C, Lee S-Y, Kim C-H, Kim Y-K, Kim K-H, Moon H-S, Song J-S, Park S-H. Comparative study on the effects of a Viscum album (L.) extract (mistletoe) and doxycycline for pleurodesis in patients with malignant pleural effusion. 51th Meeting of The Korean Association of Internal Medicine. Translation by Helixor Heilmittel GmbH. Korean Journal of Medicine. 1999;57:S121.
    1. Heiny B-M. Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema) Krebsmedizin. 1991;12:1–14.
    1. Gutsch J, Berger H, Scholz G, Denck H. Prospektive Studie beim radikal operierten Mammakarzinom mit Polychemotherapie, Helixor und unbehandelter Kontrolle. Dtsch Zschr Onkol. 1988. pp. 94–100.
    1. Lange O, Scholz G, Gutsch J. Modulation der subjektiven und objektiven Toxizität einer aggressiven Chemotherapie mit Helixor. Unpublished Report. 1985.
    1. Loewe-Mesch A, Kuehn JH, Borho K, Abel U, Bauer C, Gerhard I, Schneeweiss A, Sohn C, Strowitzki T, Hagens C. Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit. Forsch Komplementärmed. 2008;15:22–30. doi: 10.1159/000112860.
    1. Büssing A, Bischof M, Hatzmann W, Bartsch F, Soto-Vera D, Fronk E-M, Gmeindl M, Stein GM. Prevention of surgery-induced depression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res. 2005;25:4753–4758.
    1. Salzer G. 30 Jahre Erfahrung mit der Misteltherapie an öffentlichen Krankenanstalten. In: Leroi R, editor. Misteltherapie Eine Antwort auf die Herausforderung Krebs. Stuttgart, Verlag Freies Geistesleben; 1987. pp. 173–215.
    1. Fellmer Ch, Fellmer KE. Nachbehandlung bestrahlter Genitalkarzinome mit dem Viscum-album-Präparat "Iscador". Krebsarzt. 1966;21:174–185.
    1. Majewski A, Bentele W. Über Zusatzbehandlung beim weiblichen Genitalkarzinom. Zentralbl Gynäkol. 1963;85:696–700.
    1. Beuth J, Schneider B, Schierholz JM. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res. 2008;28:523–528.
    1. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B. Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Ergebnisse einer multizentrischen, komparativen, epidemiologischen Kohortenstudie in Deutschland und der Schweiz. Arzneim – Forsch/Drug Res. 2004;54:456–466.
    1. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J, Beuth J. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Anticancer Res. 2003;23:5081–5088.
    1. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J, Beuth J. Postoperative komplementäre Therapie des primären Mammakarzinoms mit lektinnormiertem Mistelextrakt – eine epidemiologische, multizentrische retrolektive Kohortenstudie. Dtsch Zschr Onkol. 2002;34:106–114. doi: 10.1055/s-2002-35141.
    1. Mansky PJ, Grem J, Wallerstedt DB, Monahan BP, Blackman MR. Mistletoe and Gemcitabine in patients with advanced cancer: A model for the phase I study of botanicals and botanical-drug interactions in cancer therapy. Integr Cancer Ther. 2003;2:345–352. doi: 10.1177/1534735403259061.
    1. Mahfouz MM, Ghaleb HA, Hamza MR, Fares L, Moussa L, Moustafua A, El-Za Wawy A, Kourashy L, Mobarak L, Saed S, Fouad F, Tony O, Tohamy A. Multicenter open labeled clinical study in advanced breast cancer patients. A preliminary report. Journal of the Egyptian Nat Cancer Inst. 1999;11:221–227.
    1. Mahfouz MM, Ghaleb HA, Zawawy A, Scheffler A. Significant tumor reduction, improvement of pain and quality of life and normalization of sleeping patterns of cancer patients treated with a high dose of mistletoe. Ann Oncol. 1998;9:129.
    1. Finelli A, Limberg R. Mistel-Lektin bei Patienten mit Tumorerkrankungen. Medizin im Bild Diagnostik und Therapie im Bild. 1998;1:1–8.
    1. Portalupi E. Neoadjuvant treatment in HPV-related CIN with Mistletoe preparation (Iscador). . Dissertation Universität Pavia 1991/1992. 1995.
    1. Werner H, Mahfouz MM, Fares L, Fouad F, Ghaleb HA, Hamza MR, Kourashy L, Mobarak AL, Moustafa A, Saed S, Zaky O, Zawawy A, Fischer S, Scheer R, Scheffler A. Zur Therapie des malignen Pleuraergusses mit einem Mistelpräparat. Der Merkurstab. 1999;52:298–301.
    1. Stumpf C, Schietzel M. Intrapleurale Instillation eines Extraktes aus Viscum album [L.] zur Behandlung maligner Pleuraergüsse. Tumordiagnose u Therapie. 1994. pp. 57–62.
    1. Friedrichson UKH. Intraperitoneal instillation of Viscum album (L.) extrat (mistletoe) for therapy and malignant ascites. Unpublished. Department of Radiology/Oncology, Community Hospital of Herdecke, University Witten/Herdecke. 1995
    1. Knöpfl-Sidler F, Viviani A, Rist L, Hensel A. Human cancer cells exhibit in vitro individual receptiveness towards different mistletoe extracts. Pharmazie. 2005;60:448–454.
    1. Zuzak T, Rist L, Viviani A, Eggenschwiler J, Mol C, Riegert U, Meyer U. Das Mistelpräparat Iscucin® – Herstellung, Analytik, Wirkung in vitro. Der Merkurstab. 2004;57:467–473.
    1. Büssing A, Schietzel D, Schietzel M, Schink M, Stein GM. Keine Stimulation in vitro kultivierter Tumorzellen durch Mistellektin. Dtsch Zschr Onkol. 2004;36:66–70. doi: 10.1055/s-2004-828263.
    1. Burger AM, Mengs U, Kelter G, Schüler JB, Fiebig HH. No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extrakt in vitro. Anticancer Res. 2003;23:3801–3806.
    1. Ramaekers FC, Harmsma M, Tusenius KJ, Schutte B, Werner M, Ramos M. Mistletoe extracts (Viscum album L.) Iscador® interact with the cell cycle machinery and target survival mechanisms in cancer cells. Medicina. 2007;67:79–84.
    1. Harmsma M, Gromme M, Ummelen M, Dignef W, Tusenius KJ, Ramaekers FC. Differential effects of Viscum album extract IscadorQu on cell cycle progression and apoptosis in cancer cells. Int J Oncol. 2004;25:1521–1529.
    1. Harmsma M, Ummelen M, Dignef W, Tusenius KJ, Ramaekers FC. Effects of mistletoe (Viscum album L.) extracts Iscador on cell cycle and survival of tumor cells. Arzneimittelforschung. 2006;56:474–482.
    1. Kelter G, Fiebig HH. Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. Arzneimittelforschung . 2006;56(6A):435–440.
    1. Maier G, Fiebig HH. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anti-Cancer Drugs. 2002;13:373–379. doi: 10.1097/00001813-200204000-00006.
    1. Kahle B, Debreczeni JÉ, Sheldrick GM, Zeeck A. Vergleichende Zytotoxizitätsstudien von Viscotoxin-Isoformen und Röntgenstruktur von Viscotoxin A3 aus Mistelextrakten. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editor. Fortschritte in der Misteltherapie Aktueller Stand der Forschung und klinischen Anwendung. Essen, KVC Verlag; 2005. pp. 83–98.
    1. Mukthar D, Pfüller U, Tonevitsky AG, Witthohn K, Schumacher U. Cell biological investigations on the use of mistletoe lectins in cancer therapy. In: Bardocz S, Pfüller U, Pusztai A, editor. COST 98 Effects of antinutrients on the nutritional value of legume diets. Luxembourg, Office for Official Publications of the European Communities; 1998. pp. 187–193.
    1. Pae H-O, Seo W-G, Oh G-S, Shin M-K, Lee H-S, Lee HS, Kim SB, Chung H-T. Potentiation of tumor necrosis factor-α-induced apoptosis by mistletoe lectin. Immunopharmacology and Immunotoxicology. 2000;22:697–709. doi: 10.3109/08923970009016433.
    1. Burger AM, Mengs U, Schüler JB, Fiebig HH. Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro. Arzneimittelforschung. 2001;51(9):748–757.
    1. Kelter G, Schierholz JM, Fischer IU, Fiebig H-H. Cytotoxic activity and absence of tumor growth stimulation of standardized mistleteo extracts in human tumor models in vitro. Anticancer Res. 2007;27:223–233.
    1. Hugo F, Schwitalla S, Niggemann B, Zänker KS, Dittmar KEJ. Viscum album extracts Iscador® P and Iscador® M counteract the growth factor induced effects in human follicular B-HNL cells and breast cancer cells. Medicina. 2007;67:90–96.
    1. Beuth J, Ko HL, Schneider H, Tawadros S, Kasper HU, Zimst H, Schierholz JM. Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. Anticancer Res. 2006;26:4451–4456.
    1. Scheffler A, Fiebig HH, Kabelitz D, Metelmann HR. Zur direkten Zytotoxizität von Mistelpräparaten. Erfahrungsheilkunde. 1993. pp. 338–346.
    1. Gabius H-J, Darro F, Remmelink M, Andre S, Kopitz J, Danguy A, Gabius S, Salmon I, Kiss R. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Investigation. 2001;19:114–126. doi: 10.1081/CNV-100000146.
    1. Kopp J, Körner I-J, Pfüller U, Göckeritz W, Eifler R, Pfüller K, Franz H. Toxicity of mistletoe lectins I, II and III on normal and malignant cells. In: Van Driessche E, Franz H, Beeckmans S, Pfüller U, Kallikorm A, Bog-Hansen TC, editor. Lectins: Biology, Biochemistry, Clinical Biochemistry. Vol. 8. Hellerup (Denmark), Textop; 1993. pp. 41–47.
    1. Wagner H, Jordan E, Zänker KS. Cell-mediated and direct cytotoxicity of purified ingredients of Viscum album. J Cancer Res Clin Oncol. 1987. p. 53.
    1. Abuharbeid S, Apel J, Sander M, Fiedler B, Langer M, Zuzarte ML, Czubayko F, Aigner A. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun. 2004;321:403–412. doi: 10.1016/j.bbrc.2004.06.160.
    1. Kienle GS, Kiene H. Die Mistel in der Onkologie Fakten und konzeptionelle Grundlagen. Stuttgart, New York, Schattauer Verlag; 2003. Stellenwert, Dosierung und Gefährlichkeit (Tumorenhancement) des ML I – immunologische Schlußfolgerungen und experimentelle Untersuchungen; pp. 301–332.
    1. Franz H. The in vivo toxicity of toxic lectins is a complex phenomenon. In: Van Driessche E, Franz H, Beeckmans S, Pfüller U, Kallikorm A, Bog-Hansen TC, editor. Lectins: Biology, Biochemistry, Clinical Biochemistry. Vol. 8. Hellerup (Denmark), Textop; 1993. pp. 5–9.
    1. Klamerth O, Vester F, Kellner G. Inhibitory effects of a protein complex from Viscum album on fibroblasts and HeLa cells. Hoppe Seylers Z Physiol Chem . 1968;349(6):863–864.
    1. Konopa J, Woynarowski JM, Lewandowska-Gumieniak M. Isolation of Viscotoxins – Cytotoxic basic polypeptides from Viscum album L. Hoppe Seylers Z Physiol Chem. 1980;361(10):1525–1533.
    1. Ulrich W, Mechelke F. Reaktion der In-vitro-Kulturen von menschlichen Fibroblasten, HeLa-Zellen und von murinen L-Zellen bei Applikationen eines Präparats aus Viscum album L. Arzneim – Forsch/Drug Res. 1980;30(II):1722–1725.
    1. Jurin M, Zarkovic N, Hrzenjak M, Ilic Z. Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology. 1993;50:393–398. doi: 10.1159/000227217.
    1. Zarkovic N, Kalisnik T, Kissel D, Konitzer M, Jurin M, Grainza S. Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10. Cancer Biother Radiopharm. 1998;13:121–131. doi: 10.1089/cbr.1998.13.121.
    1. Fritz B, Ulrich W. Flow cytometric Analysis of human cell lines after exposure to preparations from Viscum album. Planta Med. 1989;55:100–101. doi: 10.1055/s-2006-961860.
    1. Fritz B. PhD Thesis. Universität Hohenheim; 1989. Einfluss von Viscum album L. Präparaten und allopathischen Zytostatika auf Proliferation, Zellzyklus und DNA-Gehalt menschlicher Zellen in vitro.
    1. Taylor A, McKenna GF, Burlage HM. Anticancer activity of plant extracts. Texas reports on Biology and Medicine. 1956;14:538–556.
    1. Franz H. Mistletoe lectins and their A and B chains. Oncology. 1986;43:23–34. doi: 10.1159/000226417.
    1. Seeger PG. Über die Wirkung von Mistelextrakten (Iscador und Plenosol) Erfahrungsheilkunde. 1965;14:149–174.
    1. Selawry OS, Schwartz MR, Haar H. Tumor inhibitory activity of products of Loranthaceae (mistletoe) Proceedings of the American Association for Cancer Research. 1959. pp. 62–63.
    1. Snajberk G. PhD Thesis. Ludwig-Maximilians-Universität, München; 1980. Die kanzerostatischen Wirkungen spezieller Viscum-Proteine – Signifikanz und Wirkungsverlust.
    1. Drees M, Berger DP, Dengler WA, Fiebig GH. Direct cytotoxicity effects of preparations used as unconventional methods in cancer therapy in human tumor xenografts in the clonogenic assay and in nude mice. In: Arnold W, Köpf-Maier P, Micheel B, editor. Immunodeficient animals: Models for cancer research. Vol. 51. Basel, Karger Verlag; 1996. pp. 115–122.
    1. Zarkovic N, Vukovic T, Loncaric I, Miletic M, Zarkovic K, Borovic S, Cipak A, Sabolovic S, Konitzer M, Mang S. An overview on anticancer activities of the Viscum album extract Isorel®. Cancer Biother Radiopharm. 2001;16:55–62. doi: 10.1089/108497801750096041.
    1. Jurin M, Zarkovic N, Borovic S, Kissel D. Immunomodulation by the Viscum album L. preparation Isorel and its antitumorous effects. In: Scheer R, Becker H, Berg PA, editor. Grundlagen der Misteltherapie Aktueller Stand der Forschung und klinische Anwendung. Stuttgart, Hippokrates Verlag GmbH; 1996. pp. 315–324.
    1. Khwaja TA, Dias CB, Pentecost S. Recent studies on the anticancer activities of Mistletoe (Viscum album) and its alcaloids. Oncology. 1986;43:42–50. doi: 10.1159/000226419.
    1. Cebovic T, Spasic S, Popovic M. Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo. Phytotherapy Research. 2008;22:1097–1103. doi: 10.1002/ptr.2464.
    1. Kuttan G. Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract. Immunological Investigations. 1993;22:431–440. doi: 10.3109/08820139309063421.
    1. Kuttan G, Kuttan R. Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Lett. 1992:123–130. doi: 10.1016/0304-3835(92)90224-J.
    1. Kuttan G, Kuttan V, Kuttan R. Effect of a preparation from Viscum album on tumor development in vitro and in mice. Journal of Ethnopharmacology. 1990;29:35–41. doi: 10.1016/0378-8741(90)90095-B.
    1. Berger M, Schmähl D. Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors. J Cancer Res Clin Oncol. 1983:262–265. doi: 10.1007/BF00395755.
    1. Koch FE. Experimentelle Untersuchungen über lokale Beeinflussung von Impfgeschwülsten. Z Krebsforsch. 1938. pp. 325–335.
    1. Koch FE. Experimentelle Untersuchungen über entzündung- und nekroseerzeugende Wirkung von Viscum album. Z Ges Exp Med. 1938;103:740–749. doi: 10.1007/BF02609253.
    1. Linder MC, Murillo C. Mistletoe preparations prevent changes in copper metabolism which normally occur in rats with implanted tumors. Abstract 18. Proceedings from the 73rd Annual Meeting of the American Association for Cancer Research – April 28–May 1, 1982. St. Louis, Missouri; 1982. p. 5.
    1. Seitz W. Die Wirkung von Iscador (Viscum praeparatum M.) auf das Walker-Karzinosarkom der Ratte. Wien Klin Wochenschr. 1975;87:131–132.
    1. Burger AM, Mengs U, Schüler JB, Zinke H, Lentzen H, Fiebig HH. Recombinant mistletoe lectin (ML) is a potent inhibitor of tumor cell growth in vitro and in vivo. Proceedings of the American Association for Cancer Research. 1999;40:399.
    1. Timoshenko AV, Lan Y, Gabius H-J, Lala PK. Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination. effects on tumour growth, capillary leakage and nitric oxide (NO) production. Eur J Cancer. 2001;37:1910–1920. doi: 10.1016/S0959-8049(01)00156-3.
    1. Franz H. Viscaceae lectins. In: Franz H, editor. Advances in lectin research. Vol. 2. Berlin, Volk und Gesundheit; 1989. pp. 28–59.
    1. Vester F. Über die kanzerostatischen und immunogenen Eigenschaften von Mistelproteinen. Krebsgeschehen. 1977;5:106–114.
    1. Müller J. Verfahren zur Gewinnung eines Arzneimittels. (C 24971 IVa/30h), 1–12 24-5-1962 Bundesrepublik Deutschland.
    1. Schumacher U, Feldhaus S, Mengs U. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. Cancer Lett. 2000;150:171–175. doi: 10.1016/S0304-3835(99)00387-0.
    1. Ziegler R, Grossarth-Maticek R. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador) eCam. 2008
    1. Büssing A, Girke M, Heckmann C, Schad F, Ostermann T, Kröz M. Validation of the self-regulation questionnaire as a measure of health in quality of life research. Eur J Med Res. 2009;14(5):223–227.
    1. Rostock M, Huber R. Randomized and double-blind studies – demands and reality as demonstrated by two examples of mistletoe research. Forsch Komplementarmed Klass Naturheilkd . 2004;11 Suppl:18–22. doi: 10.1159/000080571.
    1. Chvetzoff G, Tannock I. Placebo Effects in Oncology. J Natl Cancer Inst. 2003;95:19–29.
    1. Kienle GS, Kiene H. The powerful placebo effect. Fact or fiction? J Clin Epidemiol. 1997;50:1311–1318. doi: 10.1016/S0895-4356(97)00203-5.
    1. Hróbjartsson A, Gøtzsche P. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344:1594–1602. doi: 10.1056/NEJM200105243442106.
    1. Wode K, Schneider T, Lundberg I, Kienle GS. Mistletoe treatment in cancer-related fatigue: a case report. Cases Journal. 2009;2:77. doi: 10.1186/1757-1626-2-77.
    1. Stone R, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Ann Oncol. 2000;11:971–975. doi: 10.1023/A:1008318932641.
    1. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. Pharmacologic treatment of cancer-related fatigue. Oncologist. 2007;12:43–51. doi: 10.1634/theoncologist.12-S1-43.
    1. Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P, Williams GC. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist. 2007;12:51–67. doi: 10.1634/theoncologist.12-S1-52.
    1. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther. 1995;57:6–15. doi: 10.1016/0009-9236(95)90260-0.
    1. Pampallona S, von Rohr E, van Wegberg B, Bernhard J, Helwig S, Heusser P, Huerny C, Schaad H, Cerny T. Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie. 2002;25:165–170. doi: 10.1159/000055227.
    1. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–1892. doi: 10.1056/NEJM200006223422507.
    1. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1886. doi: 10.1056/NEJM200006223422506.
    1. Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ . 1998;317(167):1185–1190.
    1. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trials apply?". Lancet. 2005;365:82–93. doi: 10.1016/S0140-6736(04)17670-8.
    1. Fritz P, Dippon J, Kierschke T, Siegle I, Mohring A, Moisa A, Murdter TE. Impact of mistletoe lectin binding in breast cancer. Anticancer Res. 2004;24:1187–1192.
    1. Frantz M, Jung M-L, Ribéreau-Gayon G, Anton R. Modulation of mistletoe (Viscum album L.) lectins cytotoxicity by carbohydrates and serum glycoproteins. Arzneimittelforschung . 2000;50(5):471–478.
    1. Olsnes S, Stripe F, Sandvig K, Pihl A. Isolation and characterization of Viscumin, a toxic lectin from Viscum album L. (mistletoe) The Journal of Biological Chemistry. 1982;257:13263–13270.
    1. Seifert G, Jesse P, Längler A, Reindl T, Lüth M, Lobitz S, Henze G, Prokop A, Lode HN. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett. 2008;264:218–228. doi: 10.1016/j.canlet.2008.01.036.
    1. Thies A, Dautel P, Meyer A, Pfuller U, Schumacher U. Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer. 2008;98:106–112. doi: 10.1038/sj.bjc.6604106.
    1. Pryme IF, Bardocz S, Pusztai A, Ewen SW. Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. Histol Histopathol. 2006;21:285–299.
    1. Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig HH. Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res. 2005;25:1969–1975.
    1. Antony S, Kuttan R, Kuttan G. Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Immunological Investigations. 1999;28:1–8. doi: 10.3109/08820139909022718.
    1. Antony S, Kuttan R, Kuttan G. Role of natural killer cells in Iscador mediated inhibition of metastasis by apoptive immunotherapy. Immunological Investigations. 2000;29:219–231. doi: 10.3109/08820130009060863.
    1. Teicher BA, ed . Tumor models in cancer research. Totowa, New Jersey: Humana Press; 2001.
    1. Srivastava PK. Immunotherapy of human cancer: lessons from mice. Nature Immunology. 2000;1:363–366. doi: 10.1038/80795.
    1. Céspedes MV, Casanova I, Parreño M, Mangues R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol. 2006;8:318–329. doi: 10.1007/s12094-006-0177-7.
    1. Stein GM, Berg PA. Adverse effects during therapy with mistletoe extracts. In: Büssing A, editor. Mistletoe The Genus Viscum. Amsterdam, Hardwood Academic Publishers; 2000. pp. 195–208.
    1. Bauer C, Oppel T, Rueff F, Przybilla B. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. Ann Allergy Asthma Immunol. 2005;94:86–89.
    1. Hutt N, Kopferschmitt-Kubler M, Cabalion J, Purohit A, Alt M, Pauli G. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.) Allergol Immunopathol (Madr) 2001;29:201–203.
    1. Grossarth-Maticek R, Ziegler R. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res. 2006;11:485–495.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa